Skip to main content
SpringerLink
Log in

Neoadjuvante Radiochemotherapie bei Adenokarzinomen des ösophagogastralen Übergangs

Neoadjuvant radiochemotherapy for esophagogastric junction adenocarcinomas

  • Leitthema
  • Published:
Die Onkologie Aims and scope

Zusammenfassung

Hintergrund

Die Prognose resektabler Adenokarzinome des ösophagogastralen Übergangs hat sich in den letzten Jahren leicht verbessert, bleibt aber trotz aller Fortschritte in der Diagnostik und Therapie weiterhin unbefriedigend.

Ziel der Arbeit

Ziel dieser Arbeit war es, die Datenlage zur neoadjuvanten Radiochemotherapie (nRChT) bei Adenokarzinomen des ösophagogastralen Übergangs zusammenzufassen und eine evidenzbasierte Therapieempfehlung abzugeben.

Material und Methoden

Es erfolgte eine selektive Literaturrecherche über PubMed und eine Sichtung der deutschen S3-Leitlinie.

Ergebnisse

Zur Behandlung resektabler, lokal fortgeschrittener Tumoren des ösophagogastralen Übergangs wird eine multimodale Therapie empfohlen. Diese kann in Form einer perioperativen Chemotherapie oder nRChT erfolgen. Beide Optionen sind hinsichtlich der onkologischen Ergebnisse gleichwertig.

Schlussfolgerung

Nach aktueller Studienlage soll bei lokal fortgeschrittenen Tumoren des ösophagogastralen Übergangs eine neoadjuvante Therapie erfolgen, um die Überlebensraten bei insgesamt weiterhin kritischer Prognose zu verbessern.

Abstract

Background

The outcome of resectable esophagogastric junction adenocarcinomas has improved slightly in recent years but remains unsatisfactory despite notable progress in diagnostics and therapy.

Objectives

The goal of the article is to summarize the data on neoadjuvant radiochemotherapy (nRChT) of esophagogastric junction adenocarcinomas and to provide evidence-based treatment recommendations.

Materials and methods

A selective literature search in PubMed and a review of the German S3 guideline were conducted.

Results

Multimodal treatment is recommended for locally advanced, resectable adenocarcinomas of the esophagogastric junction. Multimodal therapy can be carried out either as perioperative chemotherapy or neoadjuvant radiochemotherapy. Both options are equivalent in terms of oncological outcomes.

Conclusion

According to current studies, neoadjuvant RChT can be performed prior to surgery for locally advanced adenocarcinomas of the esophagogastric junction to improve survival rates. However, overall survival still remains unsatisfactory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Krebs – Speiseröhrenkrebs. https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Speiseroehrenkrebs/speiseroehrenkrebs_node.html. Zugegriffen: 8. Nov. 2022

  2. Rustgi AK, El-Serag HB (2015) Esophageal carcinoma. N Engl J Med 372(15):1470–1473

    Article  Google Scholar 

  3. Buas MF, Vaughan TL (2013) Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 23(1):3–9

    Article  PubMed  PubMed Central  Google Scholar 

  4. Siewert JR, Hölscher AH, Becker K, Gössner W (1987) Cardia cancer: attempt at a therapeutically relevant classification. Chirurg 58(1):25–32

    CAS  PubMed  Google Scholar 

  5. Brierley (2017) TNM classification of malignant tumours, 8. Aufl. Wiley-Blackwell, Chichester

    Google Scholar 

  6. Nishi M, Kajisa T, Akune T, Kimituki K, Nagata M (1973) Cardia cancer-proposal of cancer in the esophagogastric junction. Geka Shinryo 15:1328–1338

    Google Scholar 

  7. Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, Brown University et al (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541(7636):169–175

    Article  Google Scholar 

  8. Arnott SJ, Duncan W, Gignoux M, Hansen HS, Launois B, Nygaard K et al (2005) Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001799.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  9. Malthaner RA, Wong RK, Rumble RB, Zuraw L, Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care (2004) Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2(24):35

    Article  PubMed  PubMed Central  Google Scholar 

  10. Schwer AL, Ballonoff A, McCammon R, Rusthoven K, D’Agostino RB, Schefter TE (2009) Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys 73(2):449–455

    Article  PubMed  Google Scholar 

  11. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P et al (2005) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6(9):659–668

    Article  PubMed  Google Scholar 

  12. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R et al (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26(7):1086–1092

    Article  CAS  PubMed  Google Scholar 

  13. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098

    Article  PubMed  Google Scholar 

  14. Zhao Q, Li Y, Wang J, Zhang J, Qiao X, Tan B et al (2015) Concurrent neoadjuvant chemoradiotherapy for siewert II and III adenocarcinoma at gastroesophageal junction. Am J Med Sci 349(6):472–476

    Article  PubMed  PubMed Central  Google Scholar 

  15. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084

    Article  PubMed  Google Scholar 

  16. Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P et al (2021) Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol 39(18):1995–2004

    Article  CAS  PubMed  Google Scholar 

  17. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20

    Article  CAS  PubMed  Google Scholar 

  18. Al-Batran S‑E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393(10184):1948–1957

    Article  PubMed  Google Scholar 

  19. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB et al (2011) Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 47(3):354–360

    Article  PubMed  Google Scholar 

  20. Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S et al (2016) A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 27(4):660–667

    Article  CAS  PubMed  Google Scholar 

  21. Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M et al (2017) Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer 81:183–190

    Article  CAS  PubMed  Google Scholar 

  22. Reynolds JV, Preston SR, O’Neill B, Lowery MA, Baeksgaard L, Crosby T et al (2021) Neo-AEGIS (neoadjuvant trial in adenocarcinoma of the esophagus and esophago-gastric junction international study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (modified MAGIC or FLOT protocol). (NCT01726452). J Clin Oncol 39(15_suppl):4004–4004

    Article  Google Scholar 

  23. Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N et al (2016) ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer 16:503

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F et al (2020) RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer 20(1):886

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K et al (2018) CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 18(1):877–810

    Article  PubMed  PubMed Central  Google Scholar 

  26. Stroes CI, Schokker S, Creemers A, Molenaar RJ, Hulshof MCCM, van der Woude SO et al (2020) Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2‑positive esophageal Adenocarcinoma: TRAP study. J Clin Oncol 38(5):462–471

    Article  CAS  PubMed  Google Scholar 

  27. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G et al (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384(13):1191–1203

    Article  CAS  PubMed  Google Scholar 

  28. Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J et al (2018) Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol 19(7):965–974

    Article  PubMed  Google Scholar 

  29. Noordman BJ, Wijnhoven BPL, Lagarde SM, Boonstra JJ, Coene PPLO, Dekker JWT et al (2018) Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer 18(1):142

    Article  PubMed  PubMed Central  Google Scholar 

  30. Alakus H, Batur M, Schmidt M, Drebber U, Baldus SE, Vallböhmer D et al (2010) Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT‑1 expression. Nucl Med Commun 31(6):532–538

    Article  CAS  PubMed  Google Scholar 

  31. Wu AJ, Bosch WR, Chang DT, Hong TS, Jabbour SK, Kleinberg LR et al (2015) Expert consensus contouring guidelines for intensity modulated radiation therapy in esophageal and gastroesophageal junction cancer. Int J Radiat Oncol Biol Phys 92(4):911–920

    Article  PubMed  PubMed Central  Google Scholar 

  32. Gao X‑S, Qiao X, Wu F, Cao L, Meng X, Dong Z et al (2007) Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67(2):389–396

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Radioonkologie und Strahlentherapie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland

    Eirini Nikolaidou & Tilman Bostel

  2. Klinik für Radioonkologie und Strahlentherapie, Charité, Berlin, Augustenburger Pl. 1, 13353, Deutschland

    Eirini Nikolaidou

Authors
  1. Eirini Nikolaidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tilman Bostel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eirini Nikolaidou.

Ethics declarations

Interessenkonflikt

E. Nikolaidou und T. Bostel geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nikolaidou, E., Bostel, T. Neoadjuvante Radiochemotherapie bei Adenokarzinomen des ösophagogastralen Übergangs. Onkologie 29, 522–530 (2023). https://doi.org/10.1007/s00761-023-01317-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-023-01317-w

Schlüsselwörter

Keywords

Search

Navigation